Related Experiment Video
Updated: May 25, 2026
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment
Pedro J Modrego1, Nicolás Fayed
1Department of Neurology, Hospital Miguel Servet, Zaragoza, Spain. med009626@saludalia.com
Objective:
Amnestic mild cognitive impairment (MCI) is highly predictive of Alzheimer's disease but the pace of deterioration varies across patients. We hypothesize that magnetic resonance spectroscopy (MRS) could be a useful surrogate marker to monitor progression of cognitive impairment in patients with amnestic MCI.
Methods:
A cohort of patients with amnestic MCI underwent single-voxel (1)H-MRS at baseline and at 2-year follow-up. We included 16 patients who converted to dementia of Alzheimer type and other 16 who did not. Changes in cognitive function were compared with the changes in the metabolite levels assessed in vivo.
Results:
At baseline the converters had lower mean N-acetyl-aspartate (NAA)/creatine (Cr) ratios in the posteromedial parietal cortex (1.41) than nonconverters (1.47). Most patients tended to lose points in the Mini-Mental test after 2-year follow-up in parallel with decreases in NAA levels (r = .53; P = .002) in the posteromedial parietal cortex as well. The converters showed significant decreases in NAA levels and Cr ratios, whereas the nonconverters did not (P = .001 and .02, respectively) in this area.
Conclusion:
We conclude that MRS is a technique sensitive enough to monitor cognitive changes and progression to dementia in patients with amnestic MCI.
Insights
Magnetic resonance spectroscopy (MRS) can track cognitive decline in patients with amnestic mild cognitive impairment (MCI). Lower N-acetyl-aspartate (NAA) levels detected by MRS indicate faster progression to Alzheimer's disease.
Area of Science:
- Neuroimaging
- Biomarkers
- Cognitive Neurology
Background:
- Amnestic mild cognitive impairment (MCI) often precedes Alzheimer's disease (AD).
- The rate of cognitive decline in MCI varies significantly among individuals.
- Predictive markers for MCI progression are crucial for early intervention.
Purpose of the Study:
- To investigate magnetic resonance spectroscopy (MRS) as a surrogate marker for monitoring cognitive impairment progression in amnestic MCI.
- To correlate changes in brain metabolite levels with cognitive function decline over two years.
- To assess the utility of MRS in predicting conversion to Alzheimer's type dementia.
Main Methods:
- A cohort of 16 amnestic MCI patients who converted to dementia and 16 who did not were studied.
- Single-voxel proton (1H)-MRS was performed at baseline and 2-year follow-up.
- Cognitive function (Mini-Mental State Examination) changes were compared with in vivo metabolite levels (NAA, Cr).
Main Results:
- At baseline, converters had lower N-acetyl-aspartate (NAA)/creatine (Cr) ratios in the posteromedial parietal cortex compared to non-converters.
- Cognitive decline over two years correlated with decreased NAA levels in the posteromedial parietal cortex (r = .53; P = .002).
- Converters showed significant decreases in NAA and Cr levels, while non-converters did not (P = .001 and .02).
Conclusions:
- Magnetic resonance spectroscopy (MRS) is sensitive to cognitive changes in amnestic MCI.
- MRS can effectively monitor disease progression and predict conversion to Alzheimer's type dementia.
- MRS-detectable metabolite changes serve as valuable biomarkers for cognitive decline.
